Literature DB >> 33685317

Evaluation of transgene expression characteristics and DNA vaccination against melanoma metastasis of an intravenously injected ternary complex with biodegradable dendrigraft poly-L-lysine in mice.

Yukinobu Kodama1, Ayako Tokunaga1, Junya Hashizume1, Hiroo Nakagawa1, Hitomi Harasawa1, Tomoaki Kurosaki1, Tadahiro Nakamura1,2, Koyo Nishida2, Mikiro Nakashima2, Mitsuru Hashida3, Shigeru Kawakami2, Hitoshi Sasaki1.   

Abstract

We developed a biocompatible splenic vector for a DNA vaccine against melanoma. The splenic vector is a ternary complex composed of plasmid DNA (pDNA), biodegradable dendrigraft poly-L-lysine (DGL), and γ-polyglutamic acid (γ-PGA), the selective uptake of which by the spleen has already been demonstrated. The ternary complex containing pDNA encoding luciferase (pCMV-Luc) exhibited stronger luciferase activity for RAW264.7 mouse macrophage-like cells than naked pCMV-Luc. Although the ternary complex exhibited strong luciferase activity in the spleen after its tail vein injection, luciferase activity in the liver and spleen was significantly decreased by a pretreatment with clodronate liposomes, which depleted macrophages in the liver and spleen. These results indicate that the ternary complex is mainly transfected in macrophages and is a suitable formulation for DNA vaccination. We applied the ternary complex to a pUb-M melanoma DNA vaccine. The ternary complex containing pUb-M suppressed the growth of melanoma and lung metastasis by B16-F10 mouse melanoma cells. We also examined the acute and liver toxicities of the pUb-M ternary complex at an excess pDNA dose in mice. All mice survived the injection of the excess amount of the ternary complex. Liver toxicity was negligible in mice injected with the excess amount of the ternary complex. In conclusion, we herein confirmed that the ternary complex was mainly transfected into macrophages in the spleen after its tail vein injection. We also showed the prevention of melanoma metastasis by the DNA vaccine and the safety of the ternary complex.

Entities:  

Keywords:  DNA vaccine; Splenic vector; gene delivery; melanoma; ternary complex

Year:  2021        PMID: 33685317      PMCID: PMC7946064          DOI: 10.1080/10717544.2021.1895904

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  32 in total

1.  Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes.

Authors:  A Gautam; C L Densmore; J C Waldrep
Journal:  Mol Ther       Date:  2000-10       Impact factor: 11.454

2.  Biocompatible complex coated with glycosaminoglycan for gene delivery.

Authors:  Marie Iwanaga; Yukinobu Kodama; Takahiro Muro; Hiroo Nakagawa; Tomoaki Kurosaki; Kayoko Sato; Tadahiro Nakamura; Takashi Kitahara; Hitoshi Sasaki
Journal:  J Drug Target       Date:  2017-01-12       Impact factor: 5.121

3.  Gene delivery system of pDNA using the blood glycoprotein fetuin.

Authors:  Yukinobu Kodama; Hiroki Hanamura; Takahiro Muro; Hiroo Nakagawa; Tomoaki Kurosaki; Tadahiro Nakamura; Takashi Kitahara; Shigeru Kawakami; Mikiro Nakashima; Hitoshi Sasaki
Journal:  J Drug Target       Date:  2017-11-28       Impact factor: 5.121

4.  Side-effects of a systemic injection of linear polyethylenimine-DNA complexes.

Authors:  Patrice Chollet; Marie C Favrot; A Hurbin; Jean-Luc Coll
Journal:  J Gene Med       Date:  2002 Jan-Feb       Impact factor: 4.565

5.  Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model.

Authors:  Mahamoud Sama Cherif; Mohammed Nasir Shuaibu; Yukinobu Kodama; Tomoaki Kurosaki; Gideon Kofi Helegbe; Mihoko Kikuchi; Akitoyo Ichinose; Tetsuo Yanagi; Hitoshi Sasaki; Katsuyuki Yui; Nguyen Huy Tien; Juntra Karbwang; Kenji Hirayama
Journal:  Vaccine       Date:  2014-01-15       Impact factor: 3.641

6.  Splenic Delivery System of pDNA through Complexes Electrostatically Constructed with Protamine and Chondroitin Sulfate.

Authors:  Yukinobu Kodama; Waka Nishigaki; Tadahiro Nakamura; Shintaro Fumoto; Koyo Nishida; Tomoaki Kurosaki; Hiroo Nakagawa; Takashi Kitahara; Takahiro Muro; Hitoshi Sasaki
Journal:  Biol Pharm Bull       Date:  2018       Impact factor: 2.233

7.  Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis.

Authors:  J-H Martens; J Kzhyshkowska; M Falkowski-Hansen; K Schledzewski; A Gratchev; U Mansmann; C Schmuttermaier; E Dippel; W Koenen; F Riedel; M Sankala; K Tryggvason; L Kobzik; G Moldenhauer; B Arnold; S Goerdt
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

8.  Biodegradable nanoparticles composed of dendrigraft poly-L-lysine for gene delivery.

Authors:  Yukinobu Kodama; Tadahiro Nakamura; Tomoaki Kurosaki; Kanoko Egashira; Toyoharu Mine; Hiroo Nakagawa; Takahiro Muro; Takashi Kitahara; Norihide Higuchi; Hitoshi Sasaki
Journal:  Eur J Pharm Biopharm       Date:  2014-05-09       Impact factor: 5.571

9.  Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

Authors:  Jianda Yuan; Geoffrey Y Ku; Humilidad F Gallardo; Francesca Orlandi; Gregor Manukian; Teresa S Rasalan; Yinyan Xu; Hao Li; Shachi Vyas; Zhenyu Mu; Paul B Chapman; Susan E Krown; Katherine Panageas; Stephanie L Terzulli; Lloyd J Old; Alan N Houghton; Jedd D Wolchok
Journal:  Cancer Immun       Date:  2009-06-05

10.  Development of a DNA Vaccine for Melanoma Metastasis by Inhalation Based on an Analysis of Transgene Expression Characteristics of Naked pDNA and a Ternary Complex in Mouse Lung Tissues.

Authors:  Yukinobu Kodama; Mikiro Nakashima; Tadayuki Nagahara; Natsuko Oyama; Junya Hashizume; Hiroo Nakagawa; Hitomi Harasawa; Takahiro Muro; Tomoaki Kurosaki; Chikamasa Yamashita; Mitsuru Hashida; Takashi Kitahara; Hitoshi Sasaki; Shigeru Kawakami; Tadahiro Nakamura
Journal:  Pharmaceutics       Date:  2020-06-11       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.